Cardiovascular composition

Claim 2

A cardiovascular composition useful for treating thrombosis comprising a pharmaceutically effective carrier; an antithrombotically effective amount of a dibenzo-thiepin compound (i) having the formula: ##STR6## wherein: X is CH 2 O, OCH 2 , CH 2 CH 2 or CH═CH; Z is S, SO, or SO 2 ; R 1 is CO 2 H, CH═O, or CH 2 OH; R 2 and R 3 can each independently be hydrogen, halogen, nitro, loweralkyl, amino, N-loweralkylamino, N,N-diloweralkyl amino, loweralkanoyl, hydroxy, loweralkoxy, lower acyloxy, loweralkylthio, trifluoromethylthio, loweralkylsulfinyl, loweralkylsulfonyl, trifluoromethyl, or R 2 and R 3 , when bonded to adjacent carbon atoms, can be joined to form a 5- or 6-membered hydrocarbon ring which can optionally contain a double bond, a carbonyl group, or a hydroxyl group; and, an angiotensin converting enzyme inhibitor compound (ii) having the formula: ##STR7## wherein: R and R 6 can each independently be hydroxy, lower alkoxy, lower alkenoxy, arloweralkyloxy, amino, diloweralkylamino lower alkoxy, acylamino lower alkoxy or acyloxy lower alkoxy; R 1 is alkyl having from 1-8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio, aryloxy or arylamino, aralkyl or heteroalkyl wherein the alkyl portion has 1-3 carbon atoms, substituted aralkyl or heteroalkyl wherein the alkyl groups have 1-3 carbon atoms and the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl; R 2 and R 7 are hydrogen; R 3 is lower alkyl or amino lower alkyl; R 4 and R5 can be joined together through the carbon and nitrogen atoms to which they are attached to form a ring of the formula: ##STR8## wherein Y is CH 2 , S, or CH--OCH 3 or the pharmaceutically acceptable salts thereof wherein said aryl is a member selected from the group consisting of phenyl or naphthyl and said heteroaryl is a member selected from the group consisting of pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazoyl or thiazolyl; and, the pharmaceutically acceptable salts thereof, the weight ratio of said dibenzo-thiepin compound (i) to said angiotensin converting enzyme inhibitor compound (ii) in said composition being about 25 to 1.

Claim 3

The composition of claim 1 wherein said weight ratio is about 10 to 1.

Claim 4

The composition of claim 1 wherein said antithrombotic dibenzo-thiepin compounds of Formula I are those wherein: X is CH 2 O, OCH 2 , CH 2 CH 2 or CH═CH; Z is SO or SO 2 ; R 1 is CO 2 H, CH═O or CH 2 OH; and, R 2 and R 3 are as defined in claim 1.

Claim 5

The composition of claim 1 wherein the antithrombotic dibenzo-thiepin compounds of Formula I are those wherein: X is CH═CH; Z is SO or SO 2 ; R 1 is CO 2 H or CH 2 OH; and, R 2 and R 3 are each independently hydrogen or halogen.

Claim 6

The composition of claim 1 wherein said angiotensin converting enzyme inhibitor compounds of Formula II are those wherein: R and R 6 can each independently be hydroxy, lower alkoxy, aralkyloxy; R 2 and R 7 are hydrogen; R 3 is methyl, aminoloweralkyl; R 4 and R 5 are joined through the carbon and nitrogen atoms to form proline, 4-thiaproline or 4-methoxyproline and; R 1 is alkyl having from 1-8 carbon atoms, substituted lower alkyl wherein the alkyl group has 1-5 carbon atoms and the substituent is amino, arylthio or aryloxy, aralkyl or heteroaralkyl wherein the alkyl portion has 1-3 carbon atoms, substituted aralkyl or heteroaralkyl wherein the alkyl groups have 1-3carbon atoms and the substituent(s) is halo, dihalo, amino, aminoalkyl, hydroxy, lower alkoxy or lower alkyl; and the pharmaceutically acceptable salts thereof wherein said aryl is a member selected from the group consisting of phenyl or naphthyl and said heteroaryl is a member selected from the group consisting of pyridyl, thienyl, furyl, indolyl, benzthienyl, imidazoyl or thiazolyl.

Claim 7

The composition of claim 1 wherein said antithrombotic dibenzo-thiepin compound of Formula I is an optically pure enantiomer selected from the group: (a) dibenzo[b,f]thiepin-3-carboxylic acid; (b) dibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (c) dibenzo[b,f]thiepin-3-carboxylic acid-5,5dioxide; (d) 3-(5-tetrazolyl)dibenzo[b,f]thiepin-5,5-dioxide; (e) 3-(5-tetrazolyl)dibenzo[b,f]thiepin; (f) 3-(5-tetrazolyl)dibenzo[b,f]thiepin-5-oxide; (g) 10,11-dihydrodibenzo[b,f]thiepin-3-carboxylic acid; (h) 10,11-dihydrodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (i) 10,11-dihydrodibenzo[b,f]thiepin-3-carboxylic acid-5,5-dioxide; (j) 10,11-dihydro-3-(5-tetrazolyl)dibenzo[b,f]thiepin; (k) 10,11-dihydro-3-(5-tetrazolyl)dibenzo[b,f]thiepin-5-oxide; (L) 10,11-dihydro-3-(5-tetrazolyl)dibenzo[b,f]thiepin-5,5-dioxide; (m) 3-hydroxymethyldibenzo[b,f]thiepin; (n) 3-hydroxymethyldibenzo[b,f]thiepin-5-oxide; (o) 3-hydroxymethyldibenzo[b,f]thiepin-5,5-dioxide; (p) 8-fluoro-3-hydroxymethyldibenzo[b,f]thiepin; (q) 8-fluoro-3-hydroxymethyldibenzo[b,f]thiepin-5-oxide; (r) 8-fluoro-3-hydroxymethyldibenzo[b,f]thiepin-5,5-dioxide; (s) 3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin; (t) 3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin-5-oxide; (u) 3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin-5,5-dioxide; (v) 8-fluoro-3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin; (w) 8-fluoro-3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin-5-oxide; and, (x) 8-fluoro-3-hydroxymethyl-10,11-dihydrodibenzo[b,f]thiepin-5,5-dioxide; (y) -7-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (z) (+) 7-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (a,a) -8-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (b,b) (+) 8-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (c,c) 3-formyldibenzo[b,f]thiepin-5,5-dioxide; (d,d) 6H-dibenzo[b,e]oxathiepin-2-carboxylic acid-5,5-dioxide; and, (e,e) 6H-dibenzo[b,e]oxathiepin-9-carboxylic acid-5,5-dioxide; and, said angiotensin converting enzyme inhibitor compound II is selected from the group: (i) N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline; (ii) N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline; (iii) N-(1-ethoxycarbonyl-4-methylpentyl)-L-alanyl-L-proline; (iv) N-(1-carboxy-5-aminopentyl)-L-alanyl-L-proline; (v) N-α-(1-carboxy-3-phenylpropyl)-L-lysyl-L-proline; (vi) N-α-(1-ethoxycarbonyl-3-phenylpropyl)-L-lysyl-L-proline; (vii) N-α-[1-carboxy-3-(3-indolyl)-propyl]-L-lysyl-L-proline; (viii) N-α-[1-carboxy-3-(4-chlorophenyl)-propyl]-L-lysyl-L-proline; (ix) N-α-[1-carboxy-2-phenylthioethyl]-L-lysyl-L-proline; (x) N-α-[1-carboxy-3-(4-chlorophenyl)-propyl]-L-lysyl-trans-4-methoxy-L-proline; (xi) N-α-[1-carboxy-5-aminopentyl]-L-lysyl-L-proline; (xii) N-α-(1-carboxy-3-phenylpropyl)-L-ornithyl-L-proline; (xiii) ethyl N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-prolinate hydrochloride; (xiv) N-[1-(ethoxycarbonyl)-3-(4-imidazolyl)propyl]-L-alanyl-L-proline; (xv) N-[1-carboxy-3-(4-imidazolyl)propyl]-L-lysyl-L-proline; (xvi) N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl-L-proline; (xvii) N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline; (xviii) N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline maleate salt; (xix) N-α-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline; and, ethyl N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-prolinate hydrochloride; and, (xx) N-α-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-lysyl-L-proline.

Claim 8

The composition of claim 6 wherein said dibenzo-thiepin compound of Formula I is a member selected from the group: (c) dibenzo[b,f]thiepin-3-carboxylic acid-5,5-dioxide; (o) 3-hydroxymethyldibenzo[b,f]thiepin-5,5-dioxide; (y) -7-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (z) (+) 7-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (a,a) -8-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (b,b) (+) 8-fluorodibenzo[b,f]thiepin-3-carboxylic acid-5-oxide; (c,c) 3-formyldibenzo[b,f]thiepin-5,5-dioxide; (d,d) 6H-dibenzo[b,e]oxathiepin-2-carboxylic acid-5,5-dioxide; and, (e,e) 6H-dibenzo[b,e]oxathiepin-9-carboxylic acid-5,5-dioxide; and, said angiotensin converting enzyme inhibitor compound II is a member selected from the group consisting of: N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline; N(1(S)-carboxy-3-phenylpropyl)-L-alanyl-L-proline; N-α-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline; and, the maleate salts of said angiotensin converting enzyme inhibitor compounds.

Claim 9

The composition of claim 6 wherein said dibenzo-thiepin compound of Formula I is dibenzo[b,f]thiepin-3-carboxylic acid-5,5-dioxide and said angiotensin converting enzyme inhibitor compound of Formula II is N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline.

Claim 10

The composition of claim 6 wherein said antithrombotic dibenzo-thiepin compound of Formula I is 3-hydroxymethyldibenzo[b,f]thiepin-5,5-dioxide and said angiotensin converting enzyme inhibitor compound of Formula II is N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline.

Claim 11

The composition of claim 6 wherein said antithrombotic dibenzo-thiepin compound of Formula I is dibenzo[b,f]thiepin-3-carboxylic acid-5,5-dioxide and said angiotensin converting enzyme inhibitor compound of Formula II is N-α-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline.

Claim 12

The composition of claim 6 wherein said antithrombotic dibenzo-thiepin compound of Formula I is 3-hydroxymethyldibenzo[b,f]thiepin-5,5-dioxide and said angiotensin converting enzyme inhibitor compound of Formula II is N-α-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline.

Claim 13

A method for treating thrombosis in a patient needing said treatment which comprising an administering an effective amount of the composition of claim 1.